Europe Asthma and COPD Drugs Market Size and Trends 2025 - 2035

The Europe asthma and COPD drugs market is expected to grow from USD 11.64 billion in 2025 to USD 19.88 billion by 2035, with a CAGR of 5.50% throughout the forecast period from 2025 to 2035.

Quick Facts

• North America dominated the global market share by 38% in 2025.
• Europe is expected to experience the fastest market growth by 5.5% CAGR during the forecast period.
• By diseases, the asthma segment held the major share by 65% of the market in 2025.
• By diseases, the COPD segment is projected to expand rapidly in the market in the coming years.
• By medication class, the combination drugs segment held a 30% dominant presence in the market in 2025.
• By medication class, the inhaled corticosteroids segment will be the fastest-growing segment over the coming years.
• By distribution channel, the retail pharmacies segment led the global market by 50% in 2025.
• By distribution channel, the online pharmacies segment is anticipated to grow with the highest CAGR in the market during the studied years.

Asthma And COPD Drugs Market Overview

Asthma and COPD are common lung disorders caused by excessive airway constriction, making breathing difficullt. Asthma is a respiratory disorder characterized by bronchial narrowing and difficult breathing. Shortness of breath, chest tightness or pain, and a wheezing sound while exhaling are all symptoms of asthma. The term "Chronic Obstructive Pulmonary Disease" (COPD) refers to a group of respiratory disorders that primarily include emphysema and chronic bronchitis.

Asthma and COPD are diagnosed using X-ray imaging, a nitric oxide test, and a sputum examination. Bronchoconstriction is a common symptom of asthma and COPD and it can be treated with corticosteroids, anticholinergic drugs, and long-acting beta-agonists. Asthmatic patients may experience sudden bronchoconstriction, also known as an asthmatic attack. Bronchodilators are agents that can be used to treat an asthma attack. Bronchodilators are delivered in an emergency with a specially designed pump to provide immediate relief.

Functional pulmonary testing (spirometry, body-plethysmography) is essential for the diagnosis, severity determination, and management of both asthma and COPD. “Children who have experienced trauma, such as divorce, the death of a parent, or domestic violence, are more likely to develop asthma than other children”, according to new research.

Market Data & Statistics

• Asthma affects over 260 million people in the world and is responsible for over 450,000 deaths annually.
• COPD is considered to affect more than 400 million people and continues to be the third leading cause of death worldwide.
• As of 2025, the U.S. FDA has approved a total of 6 biologics for the treatment of asthma, and around 20 drugs for COPD treatment.

Asthma And COPD Market Top Companies

• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Merck & Co. Inc
• Grifols S.A.
• Novartis AG
• Cipla Inc.
• Abbott
• Astellas Pharma
• Hoffmann-La Roche Ltd
• Glenmark Pharmaceuticals

Segments Covered in the Report

By Diseases

• Asthma
• COPD

By Medication Class

• Combination Drugs
• Bronchodilators
• Inhaled Corticosteroids (ICS)
• Short Acting Beta Agonists (SABA)
• Long Acting Beta Agonists (LABA)
• Leukotriene Antagonists (LTA)
• Anticholinergics
• Anti-Inflammatories
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores